Topic: inflammatory bowel disease
A tool called “polygenic risk scoring” could help physicians identify who faces a high risk of serious diseases.
Blocking the signaling receptor NLRP3 could treat a range of autoimmune disorders, IFM researchers believe.
Gossamer Bio netted $230 million in series B, following its $100 million launch in January, to fund immunotherapy trials against undisclosed targets.
IFM Therapeutics is hiving off its NLRP3 stable into a subsidiary dubbed IFM Tre, which expects to advance its lead asset into phase 1 next year.
The series A will support work to treat disease through the delivery of F. prausnitzii, one of the most abundant species of bacteria in the gut.
Genentech signed a $534 million contract with Microbiotica to pan gut bacteria for biomarkers, live bacterial drugs and new targets for IBD.
Armed with $65 million in series A funding, Celsius will sequence defined patient samples to identify the individual cells responsible for disease.
Provention Bio has filed to raise up to $50 million in an IPO, which will bankroll several clinical programs.
The alliance taps into Verily’s work to stratify and analyze white blood cells—and the data abilities come from being part of the same firm as Google.
Topline data show that Arena's ulcerative colitis candidate, etrasimod, beat out placebo in phase 2.